Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Archives of Dermatological Research|April 25, 2024
Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world settingNatalia Rompoti, Irene Stefanaki, Pantelis Panagakis, et al.Biomedicines|February 25, 2023
The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic ReviewAikaterini Tsiogka, Stamatios Gregoriou, Alexander Stratigos, et al.Journal of Clinical Medicine|October 16, 2024
Association between Inflammatory Markers and Psychometric Scores in Patients with Hidradenitis SuppurativaAikaterini I Liakou, Nikolaos Rotsiamis, Andreas G Tsantes, et al.Archives of Dermatological Research|March 29, 2025
Systemic inflammation correlates with depression and lower quality of life in patients with hidradenitis suppurativa independent of disease severityNikolaos Rotsiamis, Natalia Rompoti, Aikaterini Liakou, et al.Journal of the American Academy of Dermatology|February 8, 2019
Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensusDimitrios Rigopoulos, Robert Baran, Soumiya Chiheb, et al.American Journal of Clinical Dermatology|January 24, 2024
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre StudyTiago Torres, Andrea Chiricozzi, Luis Puig, et al.Dermatology and Therapy|January 6, 2026
Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International CohortJosé Miguel Alvarenga, Jensen Yeung, Vimal Prajapati, et al.Dermatology and Therapy|June 3, 2025
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort StudyTiago Torres, Jensen Yeung, Vimal H Prajapati, et al.American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 11, 2024
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort studyAndrea Chiricozzi, Giulia Coscarella, Luis Puig, et al.Pageof 2